obesity drug glp-1 news today Chart: 1 in 8 Americans Now Use Drugs for Weight Loss Retatrutide for weight loss: Study

Conflict of interest BG has served as a consultant for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck (MSD) and Novartis as manufacturers of DPP-4 inhibitors and has received honoraria from these companies for lectures

People who participated in these trials avoided relapsing into smoking at 24 weeks and 52 weeks

Clinicians should also expect ongoing innovation in oral formulations, combination therapies, and precision medicine approaches

Rotation: Rotate injection sites weekly

Key Mechanistic Differences# Dosing Comparison# Retatrutide Dosing# In the Phase 2 trial, retatrutide was administered as once-weekly subcutaneous injections

doi: 10.1002/oby.23257